pation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies. The aim of the current document was to propose a consensus on the position and gradual implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented. The second-level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy. Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its implementation and the high cost of molecular diagnosis and biological treatment.
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| INTRODUCTION
A new paradigm to advance medical care is precision medicine (PM). 1 The four Ps of PM stand for personalized, predictive, preventive and participatory. PM encourages a convergence of omics, systems medicine, innovative health information technology and consumer-driven health care. Global multidiscipline partnerships and the right balance between research and policy priorities are needed to achieve the audacious goal of PM. Applying the principles of PM at the point of care is one of the major challenges for development of the future healthcare system.
Precision medicine is a medical model aiming at the customization of health care-with medical decisions, practices and/or products tailored to the individual patient. 2 Based on the knowledge of mechanisms of the disease, PM generally combines diagnosis and treatment to select optimal management. 3, 4 The concept of PM is not new. Clinicians have always observed that patients with similar symptoms may have different diseases, with different causes, and that treatment may have different outcomes depending on a multitude of individual external and endogenous factors. The novelty comes from the rapid technological advances, including omics, medical imaging, regenerative medicine, biobanks and registries, along with an increased computational power and innovative health information technology (HIT). This will allow real-time clinical decision support at the point of care with implementation of harmonized care based on quality criteria and patients to be treated and monitored more precisely and effectively to better meet their individual needs. 2 In addition, other providers will play a larger role in routine care for less complex cases and during follow-up.
Precision medicine is rapidly gaining more attention in molecular diagnosis-based treatment of cancer 5 and other diseases. The practical implementation of PM is however more difficult in complex diseases such as multimorbid chronic diseases. 3, 6 Nonetheless, one recent example of successful application was reported in cystic fibrosis. In 4% of the patients, the specific intervention based on the molecular mechanism can totally reverse the disorder. 7 In allergic diseases, PM principles have always been used, in particular for patients receiving allergen immunotherapy (AIT). 8 AIT is tailored to the patient's sensitization profile and it has a long-lasting and preventive effect. 9 Despite major advances in understanding allergic diseases, many patients with upper airway diseases are still uncontrolled 10, 11 and primary prevention is still unknown. Recently, a PRACTALL report highlighted the need for PM in airway diseases. 12 Chronic upper airway inflammation can be roughly divided into two major clinical entities, that is rhinitis and rhinosinusitis. The allergic phenotype is the best characterized phenotype of rhinitis from a pathophysiologic point of view. 13 The diagnosis of allergic rhinitis (AR) requires the proof of IgE-mediated hypersensitivity using appropriate skin or blood tests and the implication of the relevant allergen in eliciting the symptoms. 14 Allergic and nonallergic rhinitis often coexist, but the treatment response differs, 15 and many patients only use "over-the-counter" (OTC) medications. 16 Chronic rhinosinusitis (CRS) is classically divided into a phenotype with and without endoscopic or radiologic evidence of nasal polyps (CRSwNP and CRSsNP, respectively). 17 Both AR and CRS are characterized by inflammation and are divided into the mild, moderate and severe subgroups, and for both, anti-inflammatory medication represents the first-line treatment. 13, 17, 18 The use of nasal endoscopy and CT imaging may not be sufficient to fully appreciate the individual patients' pathology.
Endotyping of CRS on the basis of physiological, functional and pathological characteristics might provide information on the risk of disease progression or recurrence and on the best available treatments, and also helps in identifying innovative therapeutic targets for treatment. 19 The Allergic Rhinitis and its Impact on Asthma (ARIA) treatment algorithms provide evidence-based guidelines for treatment of AR. 13, 20 Multiple treatment options, strategies and approaches can be applied depending on the level of control achieved or aiming for.
In AR, AIT is recommended when pharmacotherapy is not successful, or as an alternative to long-term pharmacotherapy. Surgical reduction of the inferior turbinate(s) or correction of a septal deviation might be indicated when nasal obstruction persists as a major symptom in adequately medically treated AR patients. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) treatment algorithms provide evidence-based guidelines for treatment of CRS. 17 Anti-inflammatory medication in combination with saline douching represents the first step of treatment for CRS, with adaptation of the therapeutic regimen dependent on the degree of control. 17 Surgery is considered if prolonged medical treatment fails, but up to 40% of patients remain symptomatic despite sinus surgery. 21 Medical treatment for any condition aims at controlling the disease including clinically significant symptom reduction with improvement of quality of life and reduction of socio-economic impact of the disorder. In contrast to other diseases like asthma 22 and despite the high prevalence of AR and CRS, 23,24 the concept of control of disease has only recently been introduced in AR 10,25 and CRS. 17 However, this concept is important to define those patients with difficult-to-treat disease, representing a diagnostic and therapeutic challenge and having a large socio-economic burden. 26, 27 After defining those patients with uncontrolled disease, factors associated with lack of control can be identified, and better insights can be obtained in global airway disease control. 28 Recently, uncontrolled disease in AR and CRS has been reported to reach 35% and 40% of patients treated in academic referral centres respectively, underscoring the need for novel and better strategies of care for both AR and CRS. 21, 29 Nowadays, it is clear that there is a need to optimize treatment and embrace the principles of PM in chronic airways diseases in order to achieve a higher level of control of disease.
This review is an initiative taken by the nonprofit EUFOREA leadership in conjunction with ARIA, EPOS and AIRWAYS • Prediction of success of treatment: The treatment strategy may be guided using a recent algorithm proposed by worldwide experts. 31 Physicians treating patients with AR should be aware of the different therapeutic strategies for AR and adapt to the patients' profile (MACVIA-ARIA), preferences and needs, taking into account the availability and accessibility to the recom- 
| Third-level management of AR
Following second-line treatment, uncontrolled patients are invited to attend outpatient clinics for evaluation and advise regarding long-term therapeutic strategy. At this stage, the majority of AR patients with uncontrolled disease are seeking specialist advice.
At specialist level, a treatment plan should ideally be proposed according to the needs of the patient, the achieved level of control, the availability of medication and the long-term ambition.
All four key principles of PM should be implemented during the follow-up consultation for AR at specialist level ( Figure 2 ):
• Prediction of success of any step-down or step-up approach, with information on the expected benefits and risks of adverse events of long-term treatment • Personalized care with a treatment plan proposed on the base of the major or most bothersome symptom(s), the comorbidities, the endotype (type 2 inflammation, mixed inflammation or neurogenic inflammation and barrier impairment) and the patients' preferences, should be envisaged
| Integrated care pathways (ICPs)
A large number of AR patients do not consult physicians because they think AR symptoms are normal and/or trivial whereas AR impacts social life, school and work productivity. 13 Many AR patients use OTC drugs 16 and only a fraction have a medical consultation.
The vast majority of patients visiting GPs or specialists have moderate/severe rhinitis. [38] [39] [40] [41] [42] Integrated care pathways differ from practice guidelines as they are utilized by a multidisciplinary team and have a focus on the quality and coordination of care, thus corresponding ideally to the requests of PM implementation at the point of care. 
F I G U R E 4
Graded implementation of precision medicine in chronic rhinosinusitis (adapted from Hellings et al. 11 ). CRSwNP, chronic rhinosinusitis with nasal polyps; CRSsNP:,chronic rhinosinusitis without nasal polyps F I G U R E 3 Multisectoral care pathway for allergic rhinitis (from Bousquet et al. 35 ).
OTC, over-the-counter
After having elaborated a treatment strategy with the CRS patient, it is recommended to evaluate the degree of symptom control after a time interval of four weeks for patients with severe disease and three months for patients with mild-moderate disease.
Symptom control in CRS can be evaluated preferably by the application of the EPOS criteria for control. It is estimated that up to 50% of patients with CRS still remain symptomatic, with partially controlled or uncontrolled CRS. The latter population is seen at specialist level, for fine-tuning the diagnosis and designing an optimal therapeutic plan. All four key principles of PM should be implemented during the follow-up consultation for CRS at specialist level ( Figure 5 ):
• Prediction of success of medical versus surgical treatment, with information of CRS patients on the expected benefits of each F I G U R E 5 Precision medicine implementation in chronic rhinosinusitis. ESS, endoscopic sinus surgery; Qol, quality of life approach on the short and long term, and the risks or adverse events of both approaches. ESS is successful for most disease parameters in CRS, including asthma control, but persistent inflammation and need for postoperative medical care need to be discussed with the patient. 50 Also the balance between repetitive surgery, especially in patients with CRSwNP, and the side-effect of intensified medical treatment should be discussed.
51
• Participation of the patient in the therapeutic plan, with clear information on the goals and practical implications of different therapeutic strategies on the short and long term, including postoperative care, importance of compliance to treatment regimes and avoidance of irritants.
• Prevention of disease progression with clear approaches for suppression of inflammation versus strategies for secondary prevention of asthma.
• Personalized care with an endotype-driven treatment plan, including biological treatment for CRSwNP, based on nasal inflammatory patterns. 52 Indeed, recent evidence highlights the benefit of biological treatment in CRSwNP patients, with superiority over oral corticosteroid therapy. [53] [54] [55] Easy-to-apply biomarkers are now needed to identify those patients who might benefit from biological treatment. AR is common, has a well-defined and accessible phenotype and often known external triggers (allergens). The disease process can be mimicked in vitro and in vivo to define novel biomarkers and drug targets for PM. Despite the emerging evidence of biologicals being the future of CRSwNP care, the long-term benefits still need to be confirmed. In addition, future studies are needed to confirm the benefit of the proposed care strategy for AR and CRS on socio-economic level as well as on the level of patient satisfaction and control of disease.
| CONCLUSIONS
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